SNY — Sanofi stock price, charts and financials

QT29Sanofi

Sanofi (NASDAQ: SNY) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
42.68
-0.27-0.63%
SNYQT29Sanofi·NASDAQ
42.68-0.63%
News
Down 0.6% — Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease (globenewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E73.59EPS (ttm)0.58Insider Own-Shs Outstand2.40BPerf Week-6.28%
Market Cap102.48BForward P/E8.29EPS next Y5.15Insider Trans-Shs Float2.17BPerf Month0.16%
Enterprise Value121.89BPEG8.51EPS next Q2.03Inst Own-Short Float0.34%Perf Quarter-1.55%
Income4.63BP/S1.80EPS this Y730.32%Inst Trans-Short Ratio2.32Perf Half Y-9.71%
Sales57.07BP/B1.29EPS next Y6.93%ROA3.07%Short Interest7.37MPerf YTD-11.93%
Book/sh33.07P/C14.14EPS next 5Y8.65%ROE5.52%52W High52.68 -18.98%Perf Year-8.71%
Cash/sh3.02P/FCF5.86EPS past 3/5Y2.58% -8.40%ROIC7.41%52W Low40.89 4.38%Perf 3Y-18.67%
Dividend Est.2.42 (5.67%)EV/EBITDA8.41Sales past 3/5Y7.30% 4.34%Gross Margin72.77%Volatility2.04% 1.64%Perf 5Y-17.29%
Dividend TTM2.42 (5.67%)EV/Sales2.14EPS Y/Y TTM-75.52%Oper. Margin20.58%ATR (14)1.04Perf 10Y1.28%
Dividend Ex-DateMay 04, 2026Quick Ratio0.23Sales Y/Y TTM19.10%Profit Margin8.09%RSI (14)44.54Recom2.59
Dividend Gr. 3/5Y2.41% 4.60%Current Ratio0.99EPS Q/Q18.64%SMA20-2.35%Beta0.30Target Price49.50
Payout120.57%Debt/Eq0.28Sales Q/Q17.52%SMA50-1.74%Rel Volume0.67Prev Close42.95
Employees82,878LT Debt/Eq0.22EarningsOct 23SMA200-8.11%Avg Volume3.37MPrice42.68
IPO DateJul 01, 2002Option/ShortYes / YesEPS/Sales Surpr.9.16% 9.61%Net Debt/EBITDA2.09Volume2,261,056Change-0.63%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-08-26ReiteratedMorgan StanleyEqual Weight$52$49
May-01-26DowngradeMorgan StanleyOverweightEqual Weight$56$52
Apr-20-26ReiteratedBNP Paribas$50
Apr-20-26DowngradeExane BNP ParibasOutperformNeutral
Feb-12-26DowngradeB of A SecuritiesBuyNeutral
Jan-16-26DowngradeUBSBuyNeutral
Jan-06-26DowngradeBarclaysOverweightEqual Weight
Dec-09-25DowngradeGuggenheimBuyNeutral
Dec-08-25DowngradeJP MorganOverweightNeutral
Sep-08-25UpgradeMorgan StanleyEqual WeightOverweight
Latest News
Aug-04-26
Aug-03-26
Jul-30-26
Jul-29-26
Jul-28-26
Jul-24-26
Jul-21-26
Jul-18-26
Company

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue57,06652,70247,91345,01642,65546,32942,61742,14842,104
Cost of Goods Sold Incl. D&A15,39514,72114,28613,65912,49514,49313,86613,41713,495
Gross Profit41,67037,98133,62631,35730,16031,83628,75028,73128,609
Selling, General and Administrative Excl. Other11,45311,5549,9359,6629,19011,30010,71011,07111,635
Research and Development9,4528,8478,0007,0386,8376,7316,3076,7436,956
Other Operating Expense12,3116,7537,8457,1293,4464,195-4,3627,5004,500
Operating Income8,45310,8277,8467,52810,6879,61016,0953,4175,518
Interest Expense690706674555405446491601574
Unusual Expense
Non-Operating Income (Expense)-1,687-3,329139-359226105519551843
Net Income Before Taxes6,0766,7917,3116,61410,5089,26816,1223,3685,787
Income Taxes1,4061,1771,3031,1002,0081,8432,061136568
Consolidated Net Income4,6318,8146,0155,8418,8037,35914,0203,0855,082
Net Income From Continuing Operations4,6705,6156,0095,5148,5007,42614,0613,2325,220
Net Income4,6318,8146,0155,8418,8037,35914,0203,0855,082
EPS (Recurring)0.573.612.372.333.352.945.601.282.04
EPS (Basic, Before Extraordinaries)0.573.612.372.333.352.945.601.282.04
EPS (Diluted)0.583.612.372.333.342.945.601.282.04
EBITDA14,48614,07811,93712,32014,20813,64520,39411,94210,832
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio73.5913.4220.3621.3814.4817.018.6839.3221.26
Price To Sales Ratio1.792.242.522.772.842.712.862.982.57
Gross Margin73.0272.0770.1869.6670.7168.7267.4668.1767.95
Operating Margin14.8120.5416.3816.7225.0520.7437.778.1113.11
Net Margin8.1216.7212.5512.9820.6415.8832.907.3212.07
Shares Outstanding2,3932,4412,5032,5032,5042,5052,5072,5002,494
Market Capitalization102,133118,291120,720124,474121,269125,501121,815125,500108,265
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.